# Rethinking Early Airway Clearence Therapies

> **NCT07696338** · NA · NOT_YET_RECRUITING · sponsor: **Nicole Hamblett** · enrollment: 405 (estimated)

## Conditions studied

- Cystic Fibrosis (CF)

## Interventions

- **OTHER:** As-needed hypertonic saline (HS)
- **OTHER:** Twice daily hypertonic saline (HS)
- **OTHER:** As-needed dornase alfa (DA)
- **OTHER:** Daily dornase alfa (DA)

## Key facts

- **NCT ID:** NCT07696338
- **Lead sponsor:** Nicole Hamblett
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-15
- **Primary completion:** 2030-02-28
- **Final completion:** 2030-02-28
- **Target enrollment:** 405 (ESTIMATED)
- **Last updated:** 2026-07-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07696338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07696338, "Rethinking Early Airway Clearence Therapies". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07696338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*